Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Rapid and sustained immune tolerance to inhibitors induced by a plasma-derived, VWF-containing FVIII concentrate.

Santagostino E, Rangarajan S, Oldenburg J, Peiró-Jordan R, Jiménez-Yuste V.

Haemophilia. 2019 Mar;25(2):e110-e113. doi: 10.1111/hae.13676. Epub 2019 Feb 20. No abstract available.

PMID:
30786119
2.

Inhibitors: A Need for Eradication?

Santagostino E, Young G, Escuriola Ettingshausen C, Jimenez-Yuste V, Carcao M.

Acta Haematol. 2019 Feb 15;141(3):151-155. doi: 10.1159/000495454. [Epub ahead of print] Review.

3.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.

Blood Transfus. 2019 Feb 4:1-8. doi: 10.2450/2019.0183-18. [Epub ahead of print]

4.

Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists.

Justo Sanz R, Monzón Manzano E, Fernández Bello I, Teresa Álvarez Román M, Martín Salces M, Rivas Pollmar MI, Jiménez Yuste V, Butta NV.

Thromb Haemost. 2019 Apr;119(4):645-659. doi: 10.1055/s-0039-1678706. Epub 2019 Feb 11.

PMID:
30743272
5.

Hindfoot malalignment in adults with haemophilic ankle arthropathy: The importance of early detection and orthotic treatment.

De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT, Martin-Salces M, Jimenez-Yuste V.

Haemophilia. 2019 Jan 21. doi: 10.1111/hae.13680. [Epub ahead of print]

PMID:
30664313
6.

Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.

Fernández-Bello I, Rode F, Álvarez-Román MT, Butta NV, Rivas-Muñoz S, Hernández-Moreno AL, de la Corte-Rodríguez H, Martín-Salces M, Larsen LF, Jiménez-Yuste V.

Eur J Pharm Sci. 2019 Feb 1;128:215-221. doi: 10.1016/j.ejps.2018.12.003. Epub 2018 Dec 7.

PMID:
30529268
7.

Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score.

Jiménez-Yuste V, Álvarez-Román MT, Martín-Salces M, De la Corte-Rodríguez H, Altisent C, Parra R, Núñez R, Pérez R, García-Candel F, Bonanad S, Querol F, Alonso N, Fernández-Mosteirín N, López-Ansoar E, García-Frade LJ, Bermejo N, Pérez-González N, Gutiérrez-Pimentel MJ, Martinoli C, Fernández-Arias I, Kim HK.

Haemophilia. 2019 Jan;25(1):144-153. doi: 10.1111/hae.13628. Epub 2018 Nov 16.

PMID:
30444298
8.

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.

Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Morfini M, Zupančić-Šalek S, Santagostino E.

Eur J Haematol. 2019 Feb;102(2):111-122. doi: 10.1111/ejh.13193. Epub 2018 Dec 6.

PMID:
30411401
9.

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.

Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jiménez-Yuste V, Harder Delff P, Chowdary P.

Haemophilia. 2019 Jan;25(1):60-66. doi: 10.1111/hae.13627. Epub 2018 Nov 8.

PMID:
30408848
10.

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.

Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellin S, Moreto A, Herrero S, Soto I, Fernández-Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Quismondo NC, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Vidal F, Corrales I.

Haematologica. 2019 Mar;104(3):587-598. doi: 10.3324/haematol.2018.203166. Epub 2018 Oct 25.

11.

Point-of-care Ultrasonography in Orthopedic Management of Hemophilia: Multiple Uses of an Effective Tool.

De la Corte-Rodriguez H, Rodriguez-Merchan EC, Jimenez-Yuste V.

HSS J. 2018 Oct;14(3):307-313. doi: 10.1007/s11420-018-9604-x. Epub 2018 Mar 5. Review.

PMID:
30258338
12.

Practical aspects of extended half-life products for the treatment of haemophilia.

Lambert T, Benson G, Dolan G, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Zupančić-Šalek S, Santagostino E.

Ther Adv Hematol. 2018 Sep 6;9(9):295-308. doi: 10.1177/2040620718796429. eCollection 2018 Sep. Review.

13.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R.

N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.

14.

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.

Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jiménez-Yuste V, Hyseni A, Friedrich U, Chowdary P.

J Thromb Haemost. 2018 Nov;16(11):2184-2195. doi: 10.1111/jth.14272. Epub 2018 Sep 30.

PMID:
30137664
15.

Common themes and challenges in hemophilia care: a multinational perspective.

Stoffman J, Andersson NG, Branchford B, Batt K, D'Oiron R, Escuriola Ettingshausen C, Hart DP, Jiménez Yuste V, Kavakli K, Mancuso ME, Nogami K, Ramírez C, Wu R.

Hematology. 2019 Dec;24(1):39-48. doi: 10.1080/10245332.2018.1505225. Epub 2018 Aug 3.

PMID:
30073913
16.

Recommendations on multidisciplinary management of elective surgery in people with haemophilia.

Escobar MA, Brewer A, Caviglia H, Forsyth A, Jimenez-Yuste V, Laudenbach L, Lobet S, McLaughlin P, Oyesiku JOO, Rodriguez-Merchan EC, Shapiro A, Solimeno LP.

Haemophilia. 2018 Sep;24(5):693-702. doi: 10.1111/hae.13549. Epub 2018 Jun 26. Review.

PMID:
29944195
17.

Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.

Pérez-Rodríguez A, Batlle J, Corrales I, Borràs N, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Navarro N, Altisent C, Pérez-Montes R, Marcellini S, Moreto A, Herrero S, Soto I, Fernández Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Castro Quismondo N, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio M, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Batlle F, Vidal F, López-Fernández MF.

PLoS One. 2018 Jun 20;13(6):e0197876. doi: 10.1371/journal.pone.0197876. eCollection 2018.

18.

Head trauma in the haemophilic child and management in a paediatric emergency department: Descriptive study.

García Sánchez P, Molina Gutiérrez MÁ, Martín Sánchez J, Inisterra Viu L, García García S, Rivas Pollmar MI, Martín Salces M, Álvarez Román MT, Jiménez Yuste V.

Haemophilia. 2018 Jul;24(4):e187-e193. doi: 10.1111/hae.13526. Epub 2018 Jun 6.

PMID:
29873151
19.

Factors Involved in Maintaining Haemostasis in Patients with Myelodysplastic Syndrome.

Fernández Bello I, Jiménez-Yuste V, de Paz R, Martín Salces M, Justo Sanz R, Monzón Manzano E, Arias-Salgado EG, Álvarez Román MT, Rivas Pollmar MI, Goyanes I, Butta NV.

Thromb Haemost. 2018 Apr;118(4):734-744. doi: 10.1055/s-0038-1637733. Epub 2018 Mar 19.

PMID:
29554698
20.

The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia.

De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT, Martin-Salces M, Martinoli C, Jimenez-Yuste V.

Expert Rev Hematol. 2018 Mar;11(3):253-261. doi: 10.1080/17474086.2018.1435269. Epub 2018 Feb 15.

PMID:
29383965
21.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.

Borràs N, Batlle J, Pérez-Rodríguez A, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Vidal F, Corrales I.

Haematologica. 2017 Dec;102(12):2005-2014. doi: 10.3324/haematol.2017.168765. Epub 2017 Sep 29.

22.

The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.

Fernández-Bello I, Stenmo C, Butta N, Lind V, Ezban M, Jiménez-Yuste V.

Haemophilia. 2017 Nov;23(6):868-876. doi: 10.1111/hae.13312. Epub 2017 Aug 29.

PMID:
28851065
23.

Haemophilia B: Where are we now and what does the future hold?

Dolan G, Benson G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Ljung R, Morfini M, Zupančić Šalek S.

Blood Rev. 2018 Jan;32(1):52-60. doi: 10.1016/j.blre.2017.08.007. Epub 2017 Aug 16. Review.

PMID:
28826659
24.

Immune thrombocytopenia - in defence of the platelet count. Response to Hill.

Álvarez Román MT, Fernández Bello I, Jiménez-Yuste V, Martín Salces M, Arias-Salgado EG, Rivas Pollmar MI, Justo Sanz R, Butta NV.

Br J Haematol. 2018 Jul;182(1):130-131. doi: 10.1111/bjh.14730. Epub 2017 May 8. No abstract available.

PMID:
28480958
25.

Outcome measures for adult and pediatric hemophilia patients with inhibitors.

Hermans C, Auerswald G, Benson G, Dolan G, Duffy A, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Osooli M, Zupančić Šalek S.

Eur J Haematol. 2017 Aug;99(2):103-111. doi: 10.1111/ejh.12881. Epub 2017 Apr 25. Review.

PMID:
28332238
26.

Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors.

Álvarez-Román MT, Fernandez-Bello I, de la Corte-Rodríguez H, Hernández-Moreno AL, Martín-Salces M, Butta-Coll N, Rivas-Pollmar MI, Rivas-Muñoz S, Jiménez-Yuste V.

Haemophilia. 2017 Jan;23(1):e50-e54. doi: 10.1111/hae.13141. No abstract available.

PMID:
28074560
27.

New findings on inhibitor development: from registries to clinical studies.

Peyvandi F, Ettingshausen CE, Goudemand J, Jiménez-Yuste V, Santagostino E, Makris M.

Haemophilia. 2017 Jan;23 Suppl 1:4-13. doi: 10.1111/hae.13137. Review.

PMID:
27990784
28.

Pain and pain management in haemophilia.

Auerswald G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Šalek SZ.

Blood Coagul Fibrinolysis. 2016 Dec;27(8):845-854.

29.

Current view and outcome of ITI therapy - A change over time?

Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K, Lambert T, Rocino A, Jiménez-Yuste V, Astermark J; European Haemophilia Therapy Strategy Board (EHTSB).

Thromb Res. 2016 Dec;148:38-44. doi: 10.1016/j.thromres.2016.10.015. Epub 2016 Oct 15.

PMID:
27770665
30.

Procoagulant profile in patients with immune thrombocytopenia.

Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V, Martín-Salces M, Arias-Salgado EG, Rivas Pollmar MI, Justo Sanz R, Butta NV.

Br J Haematol. 2016 Dec;175(5):925-934. doi: 10.1111/bjh.14412. Epub 2016 Oct 21.

PMID:
27766635
31.

Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes.

Bastida JM, González-Porras JR, Jiménez C, Benito R, Ordoñez GR, Álvarez-Román MT, Fontecha ME, Janusz K, Castillo D, Fisac RM, García-Frade LJ, Aguilar C, Martínez MP, Bermejo N, Herrero S, Balanzategui A, Martin-Antorán JM, Ramos R, Cebeiro MJ, Pardal E, Aguilera C, Pérez-Gutierrez B, Prieto M, Riesco S, Mendoza MC, Benito A, Hortal Benito-Sendin A, Jiménez-Yuste V, Hernández-Rivas JM, García-Sanz R, González-Díaz M, Sarasquete ME.

Thromb Haemost. 2017 Jan 5;117(1):66-74. doi: 10.1160/TH16-05-0375. Epub 2016 Oct 13.

PMID:
27734074
32.

The burden of inhibitors in haemophilia patients.

Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S.

Thromb Haemost. 2016 Aug 31;116 Suppl 1:S10-7. doi: 10.1160/TH16-01-0049. Epub 2016 Aug 16.

PMID:
27528280
33.

The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders.

Jiménez-Yuste V, Kruse-Jarres R, Rangarajan S, Altisent C.

Thromb Haemost. 2016 Aug 31;116 Suppl 1:S1. doi: 10.1160/TH16-01-0047. Epub 2016 Aug 16. No abstract available.

PMID:
27528277
34.

Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.

Jiménez-Yuste V, Oldenburg J, Rangarajan S, Peiró-Jordán R, Santagostino E.

Haemophilia. 2016 Nov;22(6):859-865. doi: 10.1111/hae.12986. Epub 2016 Jun 22.

PMID:
27329267
35.

Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia.

Álvarez-Román MT, Rivas Pollmar MI, Bernardino JI, Lozano ML, Martín-Salces M, Fernández-Bello I, Jiménez-Yuste V, Butta NV.

AIDS. 2016 Apr 24;30(7):1141-2. doi: 10.1097/QAD.0000000000001036. No abstract available.

PMID:
27028144
36.

Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.

López-Fernández MF, Altisent Roca C, Álvarez-Román MT, Canaro Hirnyk MI, Mingot-Castellano ME, Jiménez-Yuste V, Cid Haro AR, Pérez-Garrido R, Sedano Balbas C.

Thromb Haemost. 2016 May 2;115(5):872-95. doi: 10.1160/TH15-07-0568. Epub 2016 Feb 4. Review.

PMID:
26842562
37.

Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.

Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R.

Virus Res. 2016 Feb 2;213:224-229. doi: 10.1016/j.virusres.2015.12.019. Epub 2015 Dec 29.

PMID:
26739425
38.

Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors.

Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Altisent-Roca C, Canaro-Hirnyk MI, Jiménez-Yuste V, Cid-Haro AR, Pérez-Garrido R, Sedano-Balbas C.

Eur J Haematol. 2016 May;96(5):461-74. doi: 10.1111/ejh.12730. Epub 2016 Feb 4. Review.

PMID:
26714021
39.

Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.

Šalek SZ, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Santagostino E, Lambert T.

Blood Transfus. 2017 Jan;15(1):77-84. doi: 10.2450/2015.0127-15. Epub 2015 Dec 1.

40.

Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.

Jiménez-Yuste V, Oldenburg J, Rangarajan S, Kurth MH, Bozzo J, Santagostino E.

Haemophilia. 2016 Jan;22(1):e71-4. doi: 10.1111/hae.12857. Epub 2015 Nov 27. No abstract available.

PMID:
26612826
41.

Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies.

Berntorp E, Mauser-Bunschoten E, Jiménez-Yuste V, Spears JB.

Eur J Haematol. 2015 Nov;95 Suppl 80:1-15. doi: 10.1111/ejh.12681. Review.

PMID:
26492487
42.

Managing Haemophilia for Life: 5th Haemophilia Global Summit.

Hermans C, Dolan G, Jennings I, Windyga J, Lobet S, Rodríguez-Merchán EC, Di Minno MN, Jiménez-Yuste V, O'Mahony B.

Eur J Haematol. 2015 Oct;95 Suppl 78:1-25. doi: 10.1111/ejh.12617.

PMID:
26350039
43.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.

Parra Lopez R, Nemes L, Jimenez-Yuste V, Rusen L, Cid AR, Charnigo RJ, Baumann JA, Smith L, Korth-Bradley JM, Rendo P.

Thromb Haemost. 2015 Oct;114(4):676-84. doi: 10.1160/TH14-09-0760. Epub 2015 Aug 13.

PMID:
26293201
44.

Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in Behçet Disease.

Butta NV, Fernández-Bello I, López-Longo FJ, Jiménez-Yuste V.

Semin Thromb Hemost. 2015 Sep;41(6):621-8. doi: 10.1055/s-0035-1556727. Epub 2015 Aug 15. Review.

PMID:
26276934
45.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.

Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto Mdel M, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borràs N, Vidal F.

Thromb Haemost. 2016 Jan;115(1):40-50. doi: 10.1160/TH15-04-0282. Epub 2015 Aug 6.

PMID:
26245874
46.

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.

Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group; ObsITI committee.

Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.

PMID:
26202305
47.

Tailoring care to haemophilia patients' needs: which specialty and when?

Morfini M, Benson G, Jiménez-Yuste V, Ljung R, Mannucci PM, Pasta G, Remor E, Zupančić Šalek S.

Blood Transfus. 2015 Oct;13(4):644-50. doi: 10.2450/2015.0302-14. Epub 2015 May 20. No abstract available.

48.

Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain.

Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, de la Calle F, Borobia AM, Sánchez-Seco P, Lago M, Figueira JC, Fernández-Puntero B, Viejo A, Negredo A, Nuñez C, Flores E, Carcas AJ, Jiménez-Yuste V, Lasala F, García-de-Lorenzo A, Arnalich F, Arribas JR; La Paz-Carlos III University Hospital Isolation Unit.

Lancet Respir Med. 2015 Jul;3(7):554-62. doi: 10.1016/S2213-2600(15)00180-0. Epub 2015 May 31. Review.

PMID:
26041403
49.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.

van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2015 Jul;114(1):46-55. doi: 10.1160/TH14-11-0940. Epub 2015 Apr 16.

PMID:
25879247
50.

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A.

García-Dasí M, Aznar JA, Jiménez-Yuste V, Altisent C, Bonanad S, Mingot E, Lucía F, Giménez F, López MF, Marco P, Pérez R, Fernández MÁ, Paloma MJ, Galmes B, Herrero S, García-Talavera JA.

Haemophilia. 2015 Jul;21(4):458-64. doi: 10.1111/hae.12618. Epub 2015 Feb 4.

PMID:
25649244

Supplemental Content

Loading ...
Support Center